272 related articles for article (PubMed ID: 2896139)
21. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
Rutgeerts P
Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
[TBL] [Abstract][Full Text] [Related]
23. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis.
Mantzaris GJ; Hatzis A; Petraki K; Spiliadi C; Triantaphyllou G
Dis Colon Rectum; 1994 Jan; 37(1):58-62. PubMed ID: 8287749
[TBL] [Abstract][Full Text] [Related]
24. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
Green JR; Mansfield JC; Gibson JA; Kerr GD; Thornton PC
Aliment Pharmacol Ther; 2002 Jan; 16(1):61-8. PubMed ID: 11856079
[TBL] [Abstract][Full Text] [Related]
25. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.
Dew MJ; Hughes P; Harries AD; Williams G; Evans BK; Rhodes J
Br Med J (Clin Res Ed); 1982 Oct; 285(6347):1012. PubMed ID: 6127137
[No Abstract] [Full Text] [Related]
26. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day.
Giaffer MH; Holdsworth CD; Lennard-Jones JE; Rodrigues CA; McIntyre PB; Manjunatha S; Baron JH; Barrison IG; Polson RJ; Hoare AM
Aliment Pharmacol Ther; 1992 Aug; 6(4):479-85. PubMed ID: 1358234
[TBL] [Abstract][Full Text] [Related]
27. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
Loftus EV; Kane SV; Bjorkman D
Aliment Pharmacol Ther; 2004 Jan; 19(2):179-89. PubMed ID: 14723609
[TBL] [Abstract][Full Text] [Related]
28. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
29. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
Green JR; Gibson JA; Kerr GD; Swarbrick ET; Lobo AJ; Holdsworth CD; Crowe JP; Schofield KJ; Taylor MD
Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
[TBL] [Abstract][Full Text] [Related]
30. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
Nakshabendi IM; Duncan A; Russell RI
Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343
[TBL] [Abstract][Full Text] [Related]
31. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
32. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Sun J; Yuan Y
Adv Ther; 2016 Mar; 33(3):400-9. PubMed ID: 26898569
[TBL] [Abstract][Full Text] [Related]
33. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Sun J; Yuan Y
Adv Ther; 2016 Mar; 33(3):410-22. PubMed ID: 26905266
[TBL] [Abstract][Full Text] [Related]
34. Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine.
Perrot S; Aslangul E; Szwebel T; Gadhoum H; Romnicianu S; Le Jeunne C
Int J Colorectal Dis; 2007 Sep; 22(9):1119-21. PubMed ID: 17440739
[TBL] [Abstract][Full Text] [Related]
35. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides.
Turunen U; Elomaa I; Anttila VJ; Seppälä K
Scand J Gastroenterol; 1987 Sep; 22(7):798-802. PubMed ID: 2890198
[TBL] [Abstract][Full Text] [Related]
36. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution.
Riley SA; Lecarpentier J; Mani V; Goodman MJ; Mandal BK; Turnberg LA
Gut; 1987 Aug; 28(8):1008-12. PubMed ID: 2889648
[TBL] [Abstract][Full Text] [Related]
37. Comparable efficacy of oral 5-aminosalicylic acid (Mesasal) and sulfasalazine in maintaining ulcerative colitis in remission.
Eliakim R; Wengrower D; Ligumsky M; Rachmilewitz D
Isr J Med Sci; 1990 Jan; 26(1):47-9. PubMed ID: 1968895
[No Abstract] [Full Text] [Related]
38. Review article: balsalazide therapy in ulcerative colitis.
Ragunath K; Williams JG
Aliment Pharmacol Ther; 2001 Oct; 15(10):1549-54. PubMed ID: 11563993
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and tolerability of 5-aminosalicylic acid in the short-term treatment of ulcerative rectocolitis during the mild or moderate stage].
Bresci G; Carrai M; Venturini G; Gambardella L
Minerva Dietol Gastroenterol; 1990; 36(1):31-3. PubMed ID: 1970855
[TBL] [Abstract][Full Text] [Related]
40. Lichen planus and mesalazine.
Alstead EM; Wilson AG; Farthing MJ
J Clin Gastroenterol; 1991 Jun; 13(3):335-7. PubMed ID: 1676716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
